FDA

Separation of Drug Scheduling Powers

HHS Secretary RFK Jr. has substantial power to block or constrain DEA proposals to schedule drugs, including psychedelics

Mar 20 •

Lykos MDMA therapy papers retracted by medical journal

Psychopharmacology retracted three papers by Lykos (MAPS PBC) researchers, including a meta-analysis of MDMA trials, a long-term follow up study, and a…

Aug 11, 2024 •

Teaching Psychedelic Law

A course on psychedelic law starts at Florida State University. Likely the world's first.

Aug 29, 2023 •

FDA Issues Psychedelic Research Guidance for Industry

Covers clinical trials of psilocybin, MDMA, and LSD, including the role of therapy, abuse potential, adverse events, participant blinding, investigator…

Jun 24, 2023 •

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts